Loading
A phase 3 trial of Pirtobrutinib, Venetoclax and Rituximab in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., active and no longer recruiting.
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) is a phase 3 interventional study registered as NCT04965493 by Loxo Oncology, Inc., with 600 participants enrolled, started 2021-09-20 and due to reach its primary completion in 2026-10. Interventions recorded: Pirtobrutinib, Venetoclax and Rituximab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Eli Lilly (incl. Loxo), Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Venetoclax, Rituximab and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Venetoclax, Rituximab and the tag pipeline.
Shares BCL-2 inhibitors, Relapsed or refractory chronic lymphocytic leukaemia, Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Pirtobrutinib, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/